ILMN: 3 B-Rated Biotech Stocks to Boost Your Bottom Line | StockNews.com
O-O-O-O-Ozempic
Are we still on the Ozempic kick? Seems like just last week everyone was touting it as the next miracle drug and has been benefiting heavily from that (stock's up 25% YTD)
Personally, I feel like there are some long term side effects that we just don't know yet, but maybe that's just the conspiracy theorist in me.
But, if Ozempic is some miracle drug, would it make sense to buy in now? Imagine how much a drug like that would turn the entrie market and industry in its head.
VRTX - my current Biotech of choice
(biopharmaceutical, Boston) has been up 33.02% YoY, several earnings beats and FDA approvals recently.
I'm currently bullish on them based on FDA approvals on the pipeline on product and significant value investing opportunity at this stage.
Taken below quick notes in each business indicator:
Financials: In 2023, EBITDA reached $4 billion, with revenue hitting $9.87 billion and a $13.7 billion net cash position.
Growth: 2023 revenue rose by 11%, with a projected 8% increase in 2024.
Product: Trikafta/Kaftrio earned $6.04 billion in the U.S. and $3.83 billion internationally in 2023, treating cystic fibrosis.
Pipeline: Casgevy for sickle cell disease received approvals in multiple regions in 2023.
Valuation: Vertex's enterprise value stands at $101.38 billion, with an EBITDA multiple of 25.4.
My outlook is that it's a company with solid finances and promising products, offers potential in the biotech sector.
it's Biotechin time
ILMN: 3 B-Rated Biotech Stocks to Boost Your Bottom Line | StockNews.com
Abbvie: is it undervalued?
has made a decent recovery this year, jumping 11% YTD.
But it doesn’t have translated to Wall Street, it trades at a valuation even lower than the average price-earnings ratio of the industry.
An undervalued giant of this kind could be a solid investment play as it grows its revenue base.
I’ve been thinking this more as a long term investment.
New Alzheimer's Drug Approved: Leqembi from Eisai and Biogen
Did you hear about the new Alzheimer's drug, Leqembi, from Eisai and Biogen? It's finally approved by the FDA and now Medicare coverage is on the table. But hold on, there are some speed bumps ahead! Wall Street's reaction doesn't seem too optimistic, with both Biogen and Eisai stocks taking hits. 📉 Guess they're not as excited as we are! 😅 But hey, analysts at SVB Securities still believe in the slow ramp-up and acceleration in 2024. Let's hope they're right! 💪💰
Now, let's talk about the caveats. Close monitoring and data collection for adverse events? A registry to follow patients and gather more insight into side effects? Yikes! And did you know that 17% of participants on Leqembi experienced brain bleeding during clinical trials? 😱 Let's hope that's not a common occurrence in the real world. The FDA also wants testing to identify those at higher risk for side effects. It's like hurdles after hurdles, am I right? 🏃♂️🏃♀️
But wait, there's more! Leqembi is the second attempt to target plaque buildup in the brain. And the high costs! 💸💸 Commercial payors are keeping their lips sealed, and Medicare still requires 20% coinsurance after deductible. The burden on Medicare alone could be billions annually! No wonder Bernie Sanders is concerned about bankrupting Medicare. 🙄 And let's not forget about the competition from Eli Lilly's donanemab. Can't catch a break, can they?
Despite all the challenges, Wall Street still sees some upside. Investor attention is now focused on building out the market for patient access. 🚀 UnitedHealth and CVS are expected to benefit the most from the approvals, thanks to their home infusion businesses. So, there's still hope for our investments! 🙌💼
Top Pharmaceutical Stocks to Consider for Long-term
4 Best Pharmaceutical Stocks to Buy in 2023 | The Motley Fool
Biogen Stock (BIIB) Booms After Promising Alzheimer's Drug Study
Hey fellow investors, have you heard about Biogen’s new Alzheimer’s drug? Apparently, it’s causing quite the stir on Wall Street. Shares of BIIB skyrocketed nearly 50% in pre-market trading after a promising Phase 3 study of 1,800 patients showed that their drug lecanemab reduced cognitive and functional decline by 27% relative to a placebo. Guggenheim analyst Yatin Suneja thinks that lecanemab holds mega blockbuster potential, likely in the $6-8 billion range. However, there is a caveat for investors – Biogen didn’t create the drug alone. Eisai owns the asset and will record revenues globally, while Biogen gets a 45% profit split. So, while there’s still potential for Biogen to benefit from an approval of lecanemab, it may not be as big of an opportunity as some hope. What do you think about this news? Are you bullish on BIIB? Let’s discuss in the comments!
Merck to buy RXDX
Merck to buy Prometheus Biosciences for about $11 billion